ALEXANDRIA, MN - January 24, 2026 - PRESSADVANTAGE - Individuals living with or at risk for glaucoma in the region can ...

SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

Despite updated understandings of IOP and glaucoma risk, cutoff values are still a primary influence on treatment ...

The 2025 AHA/ACC High Blood Pressure Guideline reflects the latest recommendations and advancements in hypertension research and clinical practice. This curated collection of commentaries and ...

Background/aims Up-to-date, stratified estimates of the number of individuals affected by glaucoma in the UK are lacking.

Researchers have predicted that cases of glaucoma, a common eye condition that can lead to blindness if not treated, are ...

If you were to listen to a day in the life of a veterinary ophthalmologist, you’d likely hear words and phrases you’ve never heard before. “A tubing system will be placed under your horse’s eyelid to ...

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

Single-cell transcriptomics identifies three discrete mouse trabecular meshwork subtypes and demonstrates that an Lmx1b glaucoma mutation drives mitochondrial dysfunction and elevated intraocular ...

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

Abstract: The measurement of ocular alignment is critical for the diagnosis of strabismus. Current clinical methods for assessing ocular misalignment are subjective and frequently rely on the ...